Zobrazeno 1 - 10
of 84
pro vyhledávání: '"Ilkka Liikanen"'
Autor:
Matti Kankainen, Timo Joensuu, Akseli Hemminki, Juuso Juhila, Siri Tähtinen, Otto Hemminki, Anna Kanerva, Kristian Taipale, Ilkka Liikanen, Minna Oksanen, Dafne C A Quixabeira, Saru Basnet
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
Externí odkaz:
https://doaj.org/article/8f3b74fc93134e3ea38d7aca73c18d0b
Autor:
Otto Hemminki, Minna Oksanen, Kristian Taipale, Ilkka Liikanen, Anniina Koski, Timo Joensuu, Anna Kanerva, Akseli Hemminki
Publikováno v:
Molecular Therapy: Oncolytics, Vol 9, Iss , Pp 41-50 (2018)
The first US Food and Drug Administration (FDA)- and EMA-approved oncolytic virus has been available since 2015. However, there are no markers available that would predict benefit for the individual patient. During 2007–2012, we treated 290 patient
Externí odkaz:
https://doaj.org/article/f1ee0f5650ed47c7a5c0668c663a704c
The collapse of the Soviet Union has had profound and long-lasting impacts on the societies of Eastern Europe, the South Caucasus and Central Asia, impacts which are not yet fully worked through: changes in state-society relations, a comprehensive re
Autor:
Akseli Hemminki, Anna Kanerva, Minna Oksanen, Paula Savola, Theresia Gutmann, Kilian Guse, Siri Tähtinen, Ilkka Liikanen
Breast cancer cell lines BT-474, SKBR3, JIMT-1, and MDA-MB-436 were infected with indicated viruses at increasing plaque-forming units per cell (pfu/cell). The pfu-titers were first determined for each virus in a standard tissue culture infectious do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa3966572623c501ee4c69b17792d5b9
https://doi.org/10.1158/1535-7163.22503708.v1
https://doi.org/10.1158/1535-7163.22503708.v1
Autor:
Akseli Hemminki, Anna Kanerva, Minna Oksanen, Paula Savola, Theresia Gutmann, Kilian Guse, Siri Tähtinen, Ilkka Liikanen
To confirm that observed ADCC mediated by virus-produced trastuzumab (Fig. 3) requires immune cells, supernatants from mock or Ad5/3-Î"24-tras infected 293 cells were purified and concentrated (virus-free, antibody-containing), and then added on N87
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::179e6841fa9943c5e15eef309c054aba
https://doi.org/10.1158/1535-7163.22503705
https://doi.org/10.1158/1535-7163.22503705
Autor:
Akseli Hemminki, Anna Kanerva, Minna Oksanen, Paula Savola, Theresia Gutmann, Kilian Guse, Siri Tähtinen, Ilkka Liikanen
3-4 week-old female nude/NMRI mice (Harlan Laboratories) were xenografted in both flanks with MDA-MB-436 triple-negative breast cancer cells (6Ã-106 cells/tumor). When tumors reached 5 mm in diameter, mice were randomized and treated intratumorally
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8118b8aa2ab947326c4e324dd2083e5
https://doi.org/10.1158/1535-7163.22503702.v1
https://doi.org/10.1158/1535-7163.22503702.v1
Autor:
Akseli Hemminki, Anna Kanerva, Minna Oksanen, Paula Savola, Theresia Gutmann, Kilian Guse, Siri Tähtinen, Ilkka Liikanen
A) Breast cancer BT-474, SKBR3, JIMT-1, and MDA-MB-436 cells, B) ovarian cancer OVCAR3, SKOV3, CaOV3, and HEY cells, and C) gastric N87, MKN-28, MKN-45 and esophageal cancer OE19 cells were treated with commercial or virus-produced trastuzumab (N87 c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab9748027678d8818f984e187095c203
https://doi.org/10.1158/1535-7163.22503711
https://doi.org/10.1158/1535-7163.22503711
Autor:
Akseli Hemminki, Anna Kanerva, Minna Oksanen, Paula Savola, Theresia Gutmann, Kilian Guse, Siri Tähtinen, Ilkka Liikanen
3-4 week-old male nude/NMRI mice (Taconic) bearing HER2-expressing N87 gastric cancer xenografts were treated in a mechanism of action experiment as in figure 4, but with adjusted doses: 3Ã-108 VP/tumor or saline on days 0, 4, 8, and 15, while one s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3520ebb17f8b3ae17a3046158a963fa0
https://doi.org/10.1158/1535-7163.22503696.v1
https://doi.org/10.1158/1535-7163.22503696.v1
Autor:
Akseli Hemminki, Lotta Kangasniemi, Sari Pesonen, Kalevi Kairemo, Leena Laasonen, Kaarina Partanen, Tuomo Alanko, Timo Joensuu, Saila Pesonen, Raita Heiskanen, Minna Oksanen, Siri Tähtinen, Ilkka Liikanen, Vincenzo Cerullo, Anniina Koski, Iulia Diaconu, Petri Nokisalmi, Anna Kanerva
PDF file - 100K, PBMCs were isolated from patients before and circa one month after treatment and pulsed with an adenovirus-derived peptide pool and analyzed with IFN-gamma ELISPOT.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26d9a12bcec8d4b1d859164f3d0d4004
https://doi.org/10.1158/1078-0432.22446975
https://doi.org/10.1158/1078-0432.22446975
Autor:
Akseli Hemminki, Lotta Kangasniemi, Sari Pesonen, Kalevi Kairemo, Leena Laasonen, Kaarina Partanen, Tuomo Alanko, Timo Joensuu, Saila Pesonen, Raita Heiskanen, Minna Oksanen, Siri Tähtinen, Ilkka Liikanen, Vincenzo Cerullo, Anniina Koski, Iulia Diaconu, Petri Nokisalmi, Anna Kanerva
Purpose: Multiple injections of oncolytic adenovirus could enhance immunologic response. In the first part of this article, the focus was on immunologic aspects. Sixty patients previously naïve to oncolytic virus and who had white blood cells availa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::369f9b8d7f48d80f09a3e4740a74a9d0
https://doi.org/10.1158/1078-0432.c.6520932
https://doi.org/10.1158/1078-0432.c.6520932